Tolerance and feasibility of perioperative treatment with interferon-alpha 2a in advanced cancers

International Surgery

Volumn 82, Issue 2, 1997, Pages 165-169

  Houvenaeghel, G ^a,e   Bladou, F ^a   Blache, J L ^b   Olive, D ^c   Monges, G ^d   Jacquemier, J ^d   Chaudet, H ^e   Delpero, J R ^a   Guerinel G ^a  

^a Department of Surgical Oncology ^*  (France)

^b Anesthesia   (France)

^c INSERM   (France)

^d Histopathology   (France)

^e INSTITUT PAOLI CALMETTES   (France)

Author keywords

Cancer; Immunotherapy; Interferon; Surgery

Indexed keywords

RECOMBINANT ALPHA2A INTERFERON;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD CELL COUNT; BODY TEMPERATURE; CANCER SURGERY; CELL DESTRUCTION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG TOLERABILITY; DRUG TOXICITY; FEASIBILITY STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HYPERTHERMIA; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; IMMUNOTHERAPY; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; LYMPHOKINE ACTIVATED KILLER CELL; MALE; METASTASIS; NATURAL KILLER CELL; PERIOPERATIVE PERIOD; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEVER; HUMANS; INTERFERON ALFA-2A; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; NEOPLASMS; PERIOPERATIVE CARE; PROSPECTIVE STUDIES;

EID: 0030817883     PISSN: 00208868     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Balch CM, Tilden AB, Dougherty PA, Cloud GA, Abo T. Heterogeneity of natural killer lymphocyte abnormalities in colon cancer patients. Surgery 1984;95:63-69.
2. Monson JRT, Ramsden CW, Guillou PJ. Decreased Interleukin-2 production in patients with gastrointestinal cancer. Br J Surg 1986;73:483-486.
3. Monson JRT, Ramsden CW, Giles GR. Lymphokine activated killer (LAK) cells in patients with gastro-intestinal cancer. Gut 1987;28:1420-1425.
4. Slade NS, Simmons RL, Yunis E. Immunodepression after major surgery in normal patients. Surgery 1975;78:363-372.
5. Park S, Brody JI, Wallace HA, Blakemore WS. Immuno-suppressive effect of surgery. Lancet 1971;i:53-55.
6. Lennard TW, Shenton BK, Borzotta A. The influence of surgical operations on components of the human immune system. Br J Surg 1985;72:771-773.
7. Pollock RE, Babcock GF, Romsdahl MM, Nishioka K. Surgical stress mediated suppression of murine natural killer cell cytotoxicity. Can Res 1984:44:3888-3891.
8. Pollock RE, Lotzova E, Standford SD, Romsdahl MM. Effect of surgical stress on murine natural killer cell cytotoxicity. J Immunol 1987;138:171-178.
9. Salo M. Effects of anaesthesia and surgery on the immune response. Acta Anaesth Scand 1992;36:201-220.
10. Navarro M, Lozano R, Roman A. Anesthesia and immunosuppression in an experimental model. Eur Surg Res 1990;22:317-322.
11. Hammer JH, Moesgaard F, Kehlet H. Duration of postoperative immunosuppression assessed by repeated delayed type hypersensitivity skin tests. Eur Surg Res 1992;24:133-137.
12. Shapiro J, Jersky J, Katzav S. Anesthetic drugs accelerate the progression of postoperative metastases of mouse tumors. J Clin Invest 1981;68:678-685.
13. Lundy J, Lovett EJ, Hamilton S, Conran P. Halothane, surgery, immunosuppression, and artificial pulmonary metastases. Cancer 1978;41:827-830.
14. Clarke PJ, Burton RC, Wood KJ. Allogeneic blood transfusion reduces murine pulmonary natural killer (NK) activity and enhances lung metastasis of a syngeneic tumour. Int J Cancer 1993; 55:996-1002.
15. Clarke PJ, Tarin D. Effect of pre-operative blood transfusions on tumors metastasis. Br J Surg 1987;74:520-522.
16. Waymack JP. Sequelae of blood transfusion. Infect Surg 1990; 41-47.
17. Voogt PJ, Van De Velde CJ, Brand A. Perioperative blood transfusion and cancer prognosis. Different effects of blood transfusion on prognosis of colon and breast cancer patients. Cancer 1987;59:831-843.
18. Singh SK, Marquet RL, De Bruin WF. Consequences of blood loss on growth of artificial metastases. Br J Surg 1988;75:377-379.
19. Houvenaeghel G, Baume D, Blache JL, Olive D, Francon D, Delpéro JR, Guérinel G. Surgery-induced immunosuppression in advanced cancer: immunological parameters during the perioperative period. Br J Surg 1993;80:S66.
20. Houvenaeghel G, Blache JL, Olive D, Francon D, Colonna M, Delpéro JR, Guérinel G. Immunological status, cancer and surgery. Eur J Surg Oncol 1994;20:268.
21. Brivio F, Lissoni P, Tisi E, Erba L, Barni S, Tancini G, Rescaldani R, Alderi G, Nociti V. Effects of a preoperative therapy with Interleukin-2 on surgery - induced lymphocytopenia in cancer patients. Oncology 1992;49:215-218.
22. Nichols PH, Carol WR, Ward U, Sedman PC, Primrose N. Perioperative immunotherapy with recombinant Interleukin 2 in patients undergoing surgery for colorectal cancer. Cancer Res 1992;52:5765-5769.
23. Deehan DJ, Heys SD, Walker C, Eremin O. Enhance perioperative natural cytotoxicity with recombinant interleukin-2 in patients undergoing colonic surgery. Eur J Oncol 1994;20:268.
24. Bussières E, Richaud P, Gualde N. Intra-operative electron beam radiotherapy and abdomino-pelvic surgery for cancer: influence on immunological parameters. Eur J Surg Oncol 1992;18:425-432.
25. Panis Y, Ribeiro J, Chrétien Y, Nordlinger B. Dormant liver metastases: an experimental study. Br J Surg 1992;79:221-223.
26. Heys SD, Deehan DJ, Eremin O. Interleukin 2 treatment in colorectal cancer: current results and future prospects. Eur J Surg Oncol 1994;20:622-629.
27. Cole WH, Humphrey L. Need for immunologic simulators during immunosuppression produced by major cancer surgery. Ann Surg 1985;202:9-20.
28. Sedman PC, Ramsden CW, Brennan TG, Giles GR, Guinou PJ. Effects of low dose perioperative interferon on the surgically induced suppression of antitumour immune responses. Br J Surg 1988;75:976-981.
29. Altemeir. American college of surgeons 1976: Committee on control of surgical infections. Manual on control of infection in surgical patients. Philadelphia: JB Lippincott, 1976.
30. Hanna N. Flider IJ. Role of natural killer cells in the destruction of circulating tumour emboli. J Natl Cancer Inst 1980;65:801-809.
31. Hanna N, Burton RC. Definitive evidence that natural killer (NK) cells inhibit experimental tumour metastasis in vivo. J Immunol 1981;127:1275-1758.
32. Wiltrout RH, Herberman RB, Zhang, SR, Chirirgos MA, Ortaldo JR, Green KM, Talmadge JE. Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver. J Immunol 1985;134:4267-4275.
33. Markovic SN, Knight PR, Murasko DM. Inhibition of interferon stimulation of natural killer cell activity in mice anesthetized with halothane or isoflurane. Anesthesiology 1993;78:700-706.
34. Monges G. Jacquemier J, Just-Landi S, Giovannini M, Houvenaeghel G, Olive D. Analysis by flow cytometry of differenciation antigens expression on human colonic carcinoma cells and infiltrating lymphocytes. Anal Cell Pathol 1994;6:225.
35. Jacquemire J, Monges G, Just-Landi S, Houvenaeghel G, Olive D. Flow cytometric analysis of epithelial tumour cell and infiltrating lymphocytes in breast carcinoma. Anal Cell Pathol 1994;6:242.
36. Koo JD, Fung K, Siu KF, Lee NW, Lett Z, Ho J, Wong J, Ong GB. Recovery of malignant tumour cells from the right atrium during hepatic resection for hepatocellular carcinoma. Cancer 1983; 52:1952-1956.
37. Poupon MF. The metastatic function of cancer cells as revealed by a rat sarcoma model. Cancer Revue 1986;6:50-82.